On Thursday, India and the African Union (AU) postponed the India-Africa Forum Summit (IAFS) scheduled for May 26-27 in New Delhi, citing the first confirmed Ebola case in South Kivu, Democratic Republic of Congo (DRC). The outbreak, declared a public health emergency by the World Health Organization (WHO) earlier this week, has forced a pause on high-stakes diplomatic engagements between New Delhi and 54 African nations. Here’s why this delay matters: it exposes the fragile intersection of global health crises, economic diplomacy, and shifting power dynamics in the Indo-Pacific and Africa’s “new scramble” for influence.
The Ebola Outbreak: A Geopolitical Wildcard
The DRC’s South Kivu province, where the Ebola case was confirmed, sits along the Rwandan border—a region already tense with militia activity and cross-border humanitarian flows. The WHO’s declaration of a “public health emergency of international concern” (PHEIC) on May 14 was a red flag for India, which has historically prioritized economic and strategic ties with Africa over health diplomacy. But this outbreak isn’t just about containment; it’s a test of India’s ability to balance its “Act East” policy with Africa’s growing skepticism toward Western-led global health governance.
Here’s why that matters: The IAFS was set to be the largest gathering of African leaders in India since 2015, with a $10 billion pledge for infrastructure and healthcare. The postponement risks undermining India’s narrative as a “third pole” in global affairs—one that contrasts with China’s Belt and Road Initiative (BRI) and the U.S.’s Africa Growth Opportunity Act (AGOA).
“India’s delay isn’t just about Ebola; it’s a signal that New Delhi is recalibrating its Africa strategy. The AU was pushing for concrete commitments on climate finance and vaccine equity—areas where India’s leverage is weaker than China’s. This postponement gives them breathing room to negotiate harder.”
Economic Ripples: Supply Chains and Investor Sentiment
The IAFS was poised to accelerate India-Africa trade, which hit $87 billion in 2023 but remains unbalanced—India’s exports to Africa surged 32% last year, while imports grew just 5%. The summit’s postponement introduces uncertainty for Indian pharmaceutical firms, which were eyeing AU contracts for generic drugs and COVID-19 vaccine production. Meanwhile, African nations reliant on Indian remittances (over $12 billion annually) face potential disruptions if the outbreak spreads to labor hubs like Johannesburg or Nairobi.
But there’s a catch: the delay may also benefit India’s long-term strategy. By leveraging the Ebola crisis as a “force majeure” excuse, New Delhi can reset negotiations on terms more favorable to its pharmaceutical and infrastructure lobbies. Historically, India has used health crises to insert itself into African supply chains—see its role in the 2014-15 Ebola response in West Africa, which positioned it as a low-cost alternative to Western aid.
| Metric | India-Africa Trade (2023) | China-Africa Trade (2023) | U.S.-Africa Trade (2023) |
|---|---|---|---|
| Total Value ($bn) | 87.2 | 282.3 | 48.7 |
| Indian Exports to Africa (% growth) | 32% | — | — |
| African Imports from India (% of total) | 18% | 22% | 12% |
| Remittances to Africa ($bn) | 12.4 | 45.6 | 3.1 |
Source: UNCTAD, World Bank (2024)
The AU’s Dilemma: Between Beijing and New Delhi
The postponement comes as the AU is navigating a delicate balancing act. China’s influence in Africa has deepened since the 2023 BRICS expansion, with Beijing now hosting the Africa-China Summit in September. The AU’s decision to postpone the IAFS—without canceling it outright—suggests a reluctance to alienate India, but also an awareness that New Delhi’s offer may not match China’s scale.
Here’s the geopolitical calculus: India’s $10 billion pledge pales beside China’s $40 billion in loans and grants since 2018. Yet, India’s pitch—focused on healthcare, digital infrastructure, and vaccine diplomacy—aligns with Africa’s post-pandemic priorities. The delay gives the AU time to pressure India on two fronts: first, to match China’s infrastructure commitments; second, to clarify its stance on vaccine patents, a contentious issue in AU-India relations.
“The AU isn’t just waiting for Ebola to pass; it’s using this pause to send a message. If India wants to be a serious player, it needs to stop treating Africa as a charity case and start treating it as a strategic partner with leverage.”
Global Security Implications: A Test for WHO’s Credibility
The Ebola outbreak’s impact extends beyond diplomacy. The WHO’s rapid PHEIC declaration—just days after the first case—has reignited debates about the organization’s responsiveness. For India, which has historically resisted Western-led health governance (see its stance on the COVAX initiative), the outbreak is a chance to position itself as a reliable alternative.
But the real risk lies in regional instability. South Kivu is a hotspot for the M23 rebel group, which has ties to Rwanda and Uganda. An Ebola outbreak in a conflict zone could exacerbate displacement, creating a humanitarian crisis that spills into neighboring countries. This would test India’s commitment to its “Security and Growth for All in the Region” (SAGAR) doctrine, which emphasizes peacekeeping and counterterrorism in the Indian Ocean region.
The delay also complicates India’s plans to deepen military ties with African nations. Earlier this month, India signed a defense pact with Madagascar to expand its naval base in the western Indian Ocean. If the Ebola crisis drags on, African partners may prioritize health over defense cooperation, forcing India to recalibrate its security engagements.
The Long Game: Who Gains Leverage?
Short-term, the postponement is a win for China. With the IAFS delayed, Beijing can use the vacuum to reinforce its narrative as Africa’s primary development partner. But long-term, India’s move could backfire. The AU’s frustration with Western-led health governance may push it to seek alternatives—precisely the opening India has been waiting for.
Here’s the bigger picture: The IAFS delay is a microcosm of the shifting dynamics in global health diplomacy. India’s ability to navigate this crisis will determine whether it can carve out a distinct role in Africa—or if it will remain stuck in the middle, outmaneuvered by both China and the West.
The question now isn’t just whether the summit will happen, but what shape it will take when it does. Will India’s pledge be more generous? Will the AU demand concessions on vaccine equity? And most critically, will this delay strengthen or weaken India’s hand in the continent’s “new scramble”?
One thing is clear: the Ebola outbreak has just become a geopolitical chess piece—and the players are already moving.
